Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 823 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MRI Biopsy Clear all
Completed No phase listed Observational

Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging

NCT02203136
View directory record Official record
Conditions
Bladder Cancer
Interventions
Tissue Biopsy, Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Sep 23, 2026, 5:05 PM EDT
Recruiting Phase 2 Interventional

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

NCT06368817
View directory record Official record
Conditions
Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma, Pineal Region Germinoma, Suprasellar Germinoma, Thalamic Germinoma
Interventions
3-Dimensional Conformal Proton Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Carboplatin, Etoposide, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Lumbar Puncture, Magnetic Resonance Imaging, Questionnaire Administration, Surgical Procedure
Radiation · Procedure · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 29 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
97
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 23, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

NCT02211768
View directory record Official record
Conditions
Neurofibromatosis, MPNST
Interventions
MRI, FDG-PET/CT scans, [18F]-FLT-PET/CT scans
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 23, 2026, 5:05 PM EDT
Completed Early Phase 1 Interventional

Comparison of Three Methods for Early Detection of Breast Cancer

NCT03954015
View directory record Official record
Conditions
Proliferative Breast Disease
Interventions
Contrast Enhanced imaging, Lumason
Diagnostic Test · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Sep 23, 2026, 5:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study

NCT06523868
View directory record Official record
Conditions
Cancer Diagnosis
Interventions
GRAIL Galleri
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
45 Years and older
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 23, 2026, 5:05 PM EDT
Active, not recruiting Phase 2 Interventional

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

NCT04166318
View directory record Official record
Conditions
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Capecitabine, Computed Tomography, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
659
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 438 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

NCT03092518
View directory record Official record
Conditions
Gastric Adenocarcinoma, Esophagogastric Junction, Gastric Cancer
Interventions
Surgery, Cisplatin, Mitomycin C, Sodium Thiosulfate, Tumor Biopsy, CT C/A/P, PET-CT, MRI, EKG
Procedure · Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 23, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

NCT04896073
View directory record Official record
Conditions
Adenosquamous Carcinoma of the Pancreas
Interventions
Minnelide, ECG, CT/MRI, Tumor Biopsy
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 23, 2026, 5:05 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

NCT02911142
View directory record Official record
Conditions
Primary Effusion Lymphoma, B-Cell Neoplasm
Interventions
Lenalidomide, Rituximab, Prednisone, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, CT of neck, chest, abdomen and pelvis, 18FDG-PET scan, MRI Brain, Bone marrow biopsy, EKG, Echocardiogram, Ultrasound, Bronchoscopy, Endoscopy, CXR: PA/lat/decub
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 23, 2026, 5:05 PM EDT
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

NCT07097142
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Survey Administration, Ultrahypofractionated Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
211
States / cities
Fort Smith, Arkansas • Irvine, California • La Jolla, California + 162 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 23, 2026, 5:05 PM EDT
Recruiting Phase 1 Interventional

TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

NCT07189195
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Adenocarcinoma
Interventions
TR-002
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 23, 2026, 5:05 PM EDT
Active, not recruiting Phase 2 Interventional

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

NCT05638295
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Panitumumab, Sotorasib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
180
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 135 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 23, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas

NCT00612339
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Avastin and Temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 23, 2026, 5:05 PM EDT
Completed No phase listed Observational Results available

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

NCT01909492
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Blood Draw, Lumbar Puncture
Procedure
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 23, 2026, 5:05 PM EDT
Recruiting Not applicable Interventional

Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer

NCT06517901
View directory record Official record
Conditions
Prostate Cancer, Diagnosis
Interventions
Software fusion prostate biopsy, Cognitive fusion prostate biopsy
Procedure
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older · Male only
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Burlington, Massachusetts • Albany, New York • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 23, 2026, 5:05 PM EDT
Not yet recruiting Phase 1 Interventional

Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms

NCT07679334
View directory record Official record
Conditions
Myeloproliferative Neoplasm
Interventions
Pacritinib, Venetoclax, Azacitidine, Magnetic Resonance Imaging, Computed Tomography, Bone Marrow Aspiration
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 23, 2026, 5:05 PM EDT
Suspended Phase 1Phase 2 Interventional

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

NCT07098364
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High-Grade B-Cell Lymphoma, Recurrent Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High-Grade B-Cell Lymphoma, Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma
Interventions
Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Leukapheresis, Lisocabtagene Maraleucel, Lumbar Puncture, Lymphodepletion Therapy, Multigated Acquisition Scan, Positron Emission Tomography, X-Ray Imaging, Biospecimen Collection
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2043
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 23, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Results available

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

NCT04599634
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
Interventions
Obinutuzumab, Venetoclax, Magrolimab, Acetaminophen, Diphenhydramine, Prednisone/prednisolone, Methylprednisolone, CT Scan chest/abdomen/pelvis, MRI, 18-FDG-PET, Bone Marrow Biopsy, Bone Marrow Aspiration
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 23, 2026, 5:05 PM EDT
Recruiting Phase 1 Interventional

Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe

NCT07271017
View directory record Official record
Conditions
Prostate Cancer (Diagnosis)
Interventions
Prostate biopsy
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 23, 2026, 5:05 PM EDT
Recruiting Phase 2 Interventional

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

NCT07021989
View directory record Official record
Conditions
Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Interventions
Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine, Vinorelbine, Liposomal Doxorubicin, Foresight CLARITY™ LDT, Pegfilgrastim, Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computerized tomography (CT)
Drug · Radiation · Device + 1 more
Lead sponsor
Michael Spinner, MD
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
6
States / cities
Davis, California • Fresno, California • Irvine, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 23, 2026, 5:05 PM EDT
Terminated Phase 1 Interventional

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

NCT06343376
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, EGFRt/19-28z/IL-12 CAR T-lymphocytes, Fludarabine Phosphate, Leukapheresis, Multigated Acquisition Scan, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 23, 2026, 5:05 PM EDT
Recruiting Phase 2 Interventional

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
337
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 260 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 5:05 PM EDT
Recruiting Phase 1 Interventional

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

NCT06348108
View directory record Official record
Conditions
Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions
Talquetamab, Iberdomide, Dexamethasone, Bone Marrow Biopsy
Biological · Drug · Procedure
Lead sponsor
Alfred Chung, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 23, 2026, 5:05 PM EDT
Completed Not applicable Interventional Results available

Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA

NCT02989623
View directory record Official record
Conditions
Prostate Cancer
Interventions
Copper Cu 64 TP3805, Positron Emission Tomography and Computed Tomography Scan
Radiation · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
21 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 23, 2026, 5:05 PM EDT